AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02910050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
Study NCT00623532 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Tai-chi
Study NCT02236000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy
Study NCT02236000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.
Study NCT02624791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST contact lenses
Description: spherical contact lenses worn during simulated driving tests
Study NCT02624791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Description: toric contact lenses worn during simulated driving tests
Study NCT02624791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No contact lenses
Description: simulated driving tests
Study NCT04559763 — intervention group
Intervention type: DEVICE
Intervention: Non-Invasive Controlled Hypoxia
Description: Following arterial cannulation, hypoxia is induced by reducing the percent of inspired oxygen the subject breathes while simultaneous measurements are recorded from the test pulse oximeters and arterial blood samples are collected at targeted levels of saturation.
Study NCT04559763 — intervention group
Intervention type: OTHER
Intervention: Introduction of Motion conditions: tapping or rubbing
Description: Standard motions include tapping or rubbing at periodic intervals with amplitudes of 1-2 cm and 1-4 Hz with a random variation in frequency will occur at each plateau. Each plateau will have both an interval of tapping and rubbing. Signals are recorded by a validated, computerized data acquisition system (CAS). The device values are sampled once per second and averaged over the time taken to draw the blood sample, taking into account circulation time delays and differences in device response times
Study NCT02935660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enLighten Laser
Description: Laser tattoo removal treatment
Study NCT02943239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1033
Description: REGN1033
Study NCT02943239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: REGN2477
Study NCT02943239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00400127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silesian suspension belt
Study NCT00935727 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Elastographic imaging
Description: ultrasound imaging using a specialized computer that processes the data for tissue hardness
Study NCT04305717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReDS-guided strategy
Description: A discharge scheme based on specific target value given by the device
Study NCT02341729 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ticagrelor
Description: crushed tablets and non-crushed tablets
Study NCT01577459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA with PSE
Description: TR-701 FA Oral 200 mg oral with PSE
Study NCT01577459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TR-701 FA Placebo with PSE
Description: TR-701 FA Placebo Oral 200 mg with PSE
Study NCT02707549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)
Study NCT02707549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Study NCT03736655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interposition supraciliary implant
Description: Surgical placement of an interposition supraciliary implant in the supraciliary space
Study NCT00182559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclosporin
Description: Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
Study NCT00182559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
Study NCT02155751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Lifestyle Intervention Program (NLIP)
Description: The dietary program will mimic the gestational diabetic meal plan: a) individualize total energy intake with a minimum of 2000 kcal/day (8360 kJ/day), taking into account the usual energy intake as indicated by each dietary assessment (including 3-day food intake records) with a restriction of not more than 33% total energy intake; b) adjust if necessary the total carbohydrate intake to 40-50% of total energy intake, distributing carbohydrate intake throughout the day with three balanced meals, and three snacks per day emphasizing complex carbohydrates and low glycemic index foods; c) adjust the total fat intake to 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), with the remaining 30% dedicated to protein intake; and d) meet all micronutrient and fluid needs recommended during pregnancy.
Study NCT02155751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Lifestyle Intervention Program (ELIP)
Description: The exercise program includes a walking program in which pregnant women walk for 25 minutes, 3 to 4 times per week, adding 2 minutes each week, until 40 minutes is reached and then maintained until delivery. Each woman will be given a pedometer and log sheet to keep track of daily steps and to initiate self-monitoring behaviour.
Study NCT04306406 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Raspberries
Description: Red raspberry smoothies drink
Study NCT04198753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin tape stripping
Description: Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. Tape stripping will be collected from non-lesional skin up to 30 times. These discs will then be used to evaluate proteins and lipids. With every 5 tape strips collected, transepidermal water loss measurements will be performed.
Study NCT04198753 — intervention group
Intervention type: DEVICE
Intervention: Skin barrier assessment
Description: A small device will be used to measure transepidermal water loss (TEWL), which is the quantity of water that passes from inside the body through the skin to the surrounding atmosphere via diffusion and evaporation process. The device, a probe, is simply placed against the skin surface making superficial contact and kept there for a few seconds until the measurement terminates. This will be performed at baseline and after every 5 tape strips.
Study NCT04198753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Subjects will undergo genetic testing of FLG mutation status (5mL of whole blood in lavender top tube) and vitamin D level (2mL of whole blood in red top tube) via blood draw.
Study NCT00998790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: American Medical Systems (AMS) AdVance™ Male Sling System
Description: The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
Study NCT01979627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transulnar approach interventional procedure
Study NCT01979627 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transradial approach interventional procedure
Study NCT02884310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil adapted to SPI
Study NCT02884310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil fixed
Study NCT00874692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS and sterilisation programme
Description: BMS with reduced hot water temperature and sterilisation programme
Study NCT04076189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning
Description: Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
Study NCT04076189 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No endotracheal suctioning
Description: Procedure includes: immediate initiation of positive pressure ventilation without intubation and tracheal suctioning
Study NCT03235102 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Completion of a survey
Study NCT01291459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir
Description: MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.
Study NCT02153073 — intervention group
Intervention type: DRUG
Intervention: Omega-3 fatty acid ethyl esters
Description: Omega-3 fatty acid ethyl esters granular capsules
Study NCT01689571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6001
Study NCT01689571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03922516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ULDCT
Description: Ultra-Low-Dose-CT (ULDCT) of the chest using tin filters with third-generation dual-energy CT devices. The projected dose used will be approximately 0.2 mSv per ULDCT of the chest.
Study NCT03592745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (tVNS)
Description: tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear.
Study NCT03592745 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Vagus Nerve Stimulation (tVNS)
Description: tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear. Sham tVNS means the patient is wearing the device, but it is turned off and not delivering current during the treatment. This is a placebo condition, which is used as a study control.
Study NCT00857129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Unit
Description: low-risk patients randomised to Normal Unit
Study NCT03234465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG013
Description: AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
Study NCT03234465 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
Study NCT01565213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
Study NCT01565213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MMI
Description: group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
Study NCT01565213 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAU
Description: Care as usual by the GPs
Study NCT00986414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056
Study NCT00986414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01015027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGN668
Description: 4 IV Cohorts (Dose 1, 2, 3, \& 4)
Study NCT02951312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 25mg
Description: 25 μg oral inhalation via eFlow Nebulizer, once daily
Study NCT02951312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 75mg
Description: 75 μg oral inhalation via eFlow Nebulizer, once daily
Study NCT02951312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 200mg
Description: 200 μg oral inhalation via eFlow Nebulizer, once daily
Study NCT02951312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 200mg Jet
Description: 200 μg oral inhalation via inhalation via jet nebulizer, once daily
Study NCT02951312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution 500mg
Description: 500 μg oral inhalation via eFlow nebulizer, once daily
Study NCT02951312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate Inhalation Solution1000mg
Description: 1000 μg oral inhalation via eFlow nebulizer, once daily
Study NCT02951312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
Study NCT02485665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal biofeedback device (Any Kegel)
Description: Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
Study NCT01505283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: epidural administration of 6 ml of NaCl 0.9%
Study NCT01505283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: epidural administration of sufentanil 10 µg
Study NCT01505283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: epidural administration of lidocaine 50 mg
Study NCT00597272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH conjugates with GD2L and GD3L
Description: 6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
Study NCT00808223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alefacept
Description: IM injection
Study NCT04405752 — intervention group
Intervention type: DEVICE
Intervention: 12-mm metallic biliary stent
Description: Metallic biliary stent, covered or uncovered,KEBOMED HILZO 12mm in diameter (length 4 or 6 cm).
Study NCT04405752 — intervention group
Intervention type: DEVICE
Intervention: 10-mm metallic biliary stent
Description: Biliary, metallic, covered or uncovered stent, COOK EVOLUTION 10mm in diameter (length 4 or 6 cm)
Study NCT03290625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
Study NCT03290625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
Study NCT00857129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Special birth unit
Description: Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
Study NCT04289831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Biliary Drainage (PBD)
Description: Endoscopic retrograde biliary drainage (ERBD) and stent placement was the first choice for PBD while ultrasound-guided percutaneous transhepatic biliary drainage (PTBD) was done if ERBD was not feasible. Biliary drainage was considered successful if the serum bilirubin level decreased by 50% or more within 2 weeks after the procedure. Patients with failed PBD were referred directly to surgery, while those with successful PBD were referred to surgery 4 to 6 weeks after first drainage procedure according to the latest guidelines
Study NCT04289831 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: The standard surgical procedure for operable tumors Whipple procedure with triple reconstruction, namely pancreatogastrostomy or pancreatojejunostomy,hepaticojejunostomy and gastrojejunostomy
Study NCT00879073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
Study NCT03290625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
Study NCT02217956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT03554668 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: We take blood samples at pre-op and subsequent time points, up to three months post op.
Study NCT03085654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal administration of oxytocin 24 international units per dose.
Study NCT03085654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: Intranasal administration of placebo 24 international units per dose.
Study NCT01906970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClampArt
Study NCT03208036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TDCS
Description: 1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
Study NCT03208036 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
Study NCT03208036 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Remediation
Description: Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.
Study NCT03208036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Participants complete 60 minutes of computer-based cognitive training. All tasks are adaptable in terms of difficulty and require working memory skills. Sessions always begin with N-back and complex span tasks completed concurrent with tDCS or sham stimulation. Other tasks selected from Happy Neuron software and experimental working memory tasks are used throughout the protocol.